Green Cross, COVID-19 (Plasma Therapy/Plasma Therapeutics) Theme Rises 8.45%

On the 7th, the COVID-19 (plasma treatment/plasma therapeutics) theme showed a strong performance, rising 3.22% compared to the previous day, while Green Cross, a related stock attracting attention, surged 8.45% compared to the previous day. Green Cross is known as a pharmaceutical company specializing in blood products and vaccines.

[Graph] Major stock price changes in the COVID-19 (plasma treatment/plasma therapeutics) theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Green Cross's quant financial score is 39.93 points, ranking 4th within the COVID-19 (plasma treatment/plasma therapeutics) theme, with higher stability and profitability scores than the average of other related stocks. This indicates that Green Cross's ability to respond to internal and external economic environment changes and its efficient profit-generating capacity are better compared to other stocks within the theme from a financial perspective.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm's analysis based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.